Gadoquatrane (BAY1747846) — Competitive Intelligence Brief

Gadoquatrane (BAY1747846) (Gadoquatrane (BAY1747846)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gadolinium-based contrast agent. Area: Diagnostic Imaging.

phase 3 Gadolinium-based contrast agent Water proton relaxation (T1 relaxation enhancement) Diagnostic Imaging Small molecule

Target snapshot

Gadoquatrane (BAY1747846) (Gadoquatrane (BAY1747846)) — Bayer. Gadoquatrane is a gadolinium-based contrast agent designed for magnetic resonance imaging (MRI) that provides enhanced visualization of blood vessels and tissues.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gadoquatrane (BAY1747846) TARGET	Gadoquatrane (BAY1747846)	Bayer	phase 3	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)
Gadavist	GADOBUTROL	Bayer	marketed	Gadolinium-based Contrast Agent [EPC]		2011-01-01
DOTAREM	DOTAREM	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 and T2 relaxation times)
MultiHance 0.05 mmol/kg	MultiHance 0.05 mmol/kg	Bracco Diagnostics, Inc	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)
Gadoteric Acid Meglumine Salt	Gadoteric Acid Meglumine Salt	The Central Hospital of Lishui City	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)
Gadopentetate-Dimeglumine 0.05 mmol	Gadopentetate-Dimeglumine 0.05 mmol	Paracelsus Medical University	marketed	Gadolinium-based contrast agent	Water protons (T1 relaxation enhancement)
Dotarem®-enhanced MRI	Dotarem®-enhanced MRI	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gadolinium-based contrast agent class)

1. Guerbet · 4 drugs in this class
2. Bayer · 4 drugs in this class
3. Paracelsus Medical University · 2 drugs in this class
4. GE Healthcare · 1 drug in this class
5. Bracco Diagnostics, Inc · 1 drug in this class
6. Seoul National University Hospital · 1 drug in this class
7. Shanghai Shengdi Pharmaceutical Co., Ltd · 1 drug in this class
8. The Central Hospital of Lishui City · 1 drug in this class